ADAP - Adaptimmune Therapeutics Plc

https://www.adaptimmune.com

Momentum: Bearish

Recent News

This Albemarle Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Benzinga • 1 month, 2 weeks ago • score: 0.17

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Bullish

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Adaptimmune Therapeutics ( NASDAQ:ADAP ) , ASML Holding ( NASDAQ:ASML )

Benzinga • 2 months, 2 weeks ago • score: 0.21

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.

52W High

$1.17

52W Low

$0.04

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.24

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.71

EV/Revenue (<3 favorable)

0.55

P/S (TTM) (<3 favorable)

0.21

P/B (<3 favorable)

2.68

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.63%

Institutions (25–75% balanced)

31.35%

Shares Outstanding

265,052,000

Float

1,185,258,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

65,085,000

Gross Profit (TTM)

-63,606,000

EPS (TTM)

-0.66

Profit Margin (>10% good)

-2.61%

Operating Margin (TTM) (higher better)

-2.22%

ROE (TTM) (>15% strong)

-13.41%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.89

Momentum

Bearish momentum

Value

-0.0217

-0.0239

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025